April 26, 2018 6:46 AM ET


Company Overview of Wyeth LLC

Company Overview

Wyeth LLC develops, manufactures, distributes, and markets pharmaceutical products the United States, the United Kingdom, and internationally. The company’s Pharmaceuticals segment offers neuroscience therapies, vaccines, musculoskeletal therapies, nutritional products, gastroenterology drugs, anti-infectives, oncology therapies, hemophilia treatments, immunological products, and women's healthcare products. It offers its products to wholesalers, pharmacies, hospitals, governments, physicians, retailers, and other human healthcare institutions. The company's Consumer Healthcare segment develops, manufactures, distributes, and markets over-the-counter healthcare products comprising analgesics...

235 East 42nd Street

New York, NY 10017-5703

United States

Founded in 1926

47,426 Employees





Key Executives for Wyeth LLC

Chief Counsel and Senior Vice President
Age: 61
Executive Vice President of Technical Operations and Product Supply Operational Excellence
Age: 67
Principal Corporate Officer and Vice President of Internal Audit
Vice President of Taxes
Age: 76
Compensation as of Fiscal Year 2017.

Wyeth LLC Key Developments

A United States Appeals Court Revives an Antitrust Lawsuit against Ranbaxy, Pfizer, Wyeth and Teva

A United States appeals court has revived an antitrust lawsuit against four drug makers, alleging that they hamstrung generics for Lipitor and Effexor XR. The plaintiffs, a coalition of labor unions and retailers, including Rite Aid and Walgreens, accused four drug makers of reverse settlement payment deals, in which a drug’s patent holder pays the accused infringer not to produce the patented item. The plaintiffs allege Ranbaxy accepted such payments from Pfizer to delay generics for Lipitor, while Wyeth accepted payments from Teva to delay Effexor XR. A federal judge earlier dismissed the claims, but this week the U.S. Court of Appeals for the Third Circuit in Philadelphia reversed the ruling.

Catalyst Biosciences, Inc. Completes Manufacturing Agreements for its Novel Factor VIIa Product, Marzeptacog alpha (activated)

Catalyst Biosciences Inc. announced it has secured all rights to the manufacturing process for marzeptacog alfa (activated) (formerly known as CB 813d) from Wyeth LLC, a wholly-owned subsidiary of Pfizer. Marzeptacog alfa (activated) is a next-generation Factor VIIa product that was designed to allow for the effective, long-term, subcutaneous prophylaxis in hemophilia patients with inhibitors. Catalyst has successfully completed an intravenous Phase 1 clinical trial of marzeptacog alfa (activated) in patients with severe hemophilia A and B with and without inhibitors and has demonstrated the feasibility of subcutaneous dosing in preclinical models. In addition, the company announced that it has signed a drug product fill-finish manufacturing services agreement with Symbiosis Pharmaceutical Services Limited for marzeptacog alfa (activated) for clinical trial applications. This agreement, and the previously announced drug substance manufacturing agreement with CMC Biologics, provides Catalyst Biosciences with complete manufacturing capabilities to enable cGMP manufacturing of marzeptacog alfa (activated).

Catalyst Biosciences, Inc. Enters into Research and License Agreement with Wyeth LLC

On December 8, 2016, Catalyst Biosciences Inc. entered into a definitive agreement with Wyeth LLC (Wyeth) following the June 1, 2015 termination of the research and license agreement that was entered into on June 29, 2009 between the company and Wyeth to collaborate on the development of novel human Factor VIIa products. Pursuant to the agreement, Wyeth has granted the company an exclusive license to Wyeth's proprietary rights that apply to Factor VIIa variants, CB 813a and CB 813d, to research, develop, manufacture and commercialize the Products. Wyeth has also transferred and will transfer to the company documentation related to the development, manufacturing and testing of the Products, including the Investigational New Drug application. In connection with the license granted by Wyeth to the company, the company agreed to make contingent cash payments to Wyeth in an aggregate amount equal to up to $17.5 million, payable upon the achievement of clinical, regulatory and commercial milestones. Following commercialization of any Product, Wyeth would also receive a single-digit royalty on net Product sales on a country-by-country basis for a predefined royalty term.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Wyeth LLC, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.